CIML NK Cells With Venetoclax for AML

The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML) with measurable residual disease or oligoblastic (\< 20% blasts in the bone marrow) disease. Names of the study therapies involved in this study are: * Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell infusion * CIML NK (a cellular therapy) * IL-2 (a recombinant, human glycopr

Trial Details

NCT ID

NCT06152809

Phase

PHASE1

Sponsor

Dana-Farber Cancer Institute

Status

RECRUITING

Cancer Type

Leukemia

Interventions

Cytokine-Induced Memory-like Natural Killer Cells
Interleukin-2
Venetoclax

Locations (sample)

Boston, Massachusetts, United States|42.35843,-71.05977
Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

Diagnosis of AML or MDS/AML (10-19% blasts) by 2022 ELN criteria. Historical test results (either peripheral blood or bone marrow) can be used to e…
Age ≥ 18 years old
At time of screening patient has received any prior lines of therapy including prior chemotherapy and any prior stem cell transplant, provided that…
Presence of molecular risk factors for relapse as defined by any of the following present at any time during a participant's history of AML:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →